Find Gevatran manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Iridus, Ls 121, Diethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoyl]oxyethyl]azanium;2-hydroxy-2-oxoacetate, 5adb8d9388, Naphtidrofuryl oxalate, Einecs 221-703-0
Molecular Formula
C26H35NO7
Molecular Weight
473.6  g/mol
InChI Key
SSAJNPNVUYMUCI-UHFFFAOYSA-N

Gevatran
A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
1 2D Structure

Gevatran

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
diethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoyl]oxyethyl]azanium;2-hydroxy-2-oxoacetate
2.1.2 InChI
InChI=1S/C24H33NO3.C2H2O4/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;3-1(4)2(5)6/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;(H,3,4)(H,5,6)
2.1.3 InChI Key
SSAJNPNVUYMUCI-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC[NH+](CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Artocoron

2. Azunaftil

3. Di Actane

4. Di-actane

5. Dusodril

6. Gvatran

7. Ls 121

8. Ls-121

9. Ls121

10. Nafronyl

11. Nafronyl Oxalate

12. Nafronyloxalate

13. Nafti Puren

14. Nafti Ratiopharm

15. Nafti Von Ct

16. Nafti-puren

17. Nafti-ratiopharm

18. Naftidrofuryl

19. Naftifurin Oxalate

20. Naftilong

21. Naftilux

22. Naftiratiopharm

23. Oxalate, Nafronyl

24. Oxalate, Naftifurin

25. Praxilne

2.2.2 Depositor-Supplied Synonyms

1. Iridus

2. Ls 121

3. Diethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoyl]oxyethyl]azanium;2-hydroxy-2-oxoacetate

4. 5adb8d9388

5. Naphtidrofuryl Oxalate

6. Einecs 221-703-0

7. Nsc 225233

8. Unii-5adb8d9388

9. 2-(diethylamino)ethyl Tetrahydro-alpha-(1-naphthylmethyl)-2-furanpropionate Oxalate (1:1)

10. 2-furanpropanoic Acid, Tetrahydro-alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl Ester, Ethanedioate (1:1)

11. 2-furanpropionic Acid, Tetrahydro-alpha-(1-naphthylmethyl)-, 2-(diethylamino)ethyl Ester, Oxalate (1:1)

12. Diethyl(2-(2-(1-naphthylmethyl)-3-(tetrahydro-2-furyl)propionyloxy)ethyl)ammonium Hydrogen Oxalate

2.3 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 473.6 g/mol
Molecular Formula C26H35NO7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count11
Exact Mass473.24135246 g/mol
Monoisotopic Mass473.24135246 g/mol
Topological Polar Surface Area117 Ų
Heavy Atom Count34
Formal Charge0
Complexity543
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count2
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Serotonin Antagonists

Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)


Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty